Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 158.1 USD -2.15% Market Closed
Market Cap: 9.5B USD

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 226.12 USD with a low forecast of 195.94 USD and a high forecast of 303.45 USD.

Lowest
Price Target
195.94 USD
24% Upside
Average
Price Target
226.12 USD
43% Upside
Highest
Price Target
303.45 USD
92% Upside
Ascendis Pharma A/S Competitors:
Price Targets
688373
Shanghai MicuRx Pharmaceutical Co Ltd
15% Downside
4597
Solasia Pharma KK
78% Upside
BMRN
Biomarin Pharmaceutical Inc
69% Upside
FYB
Formycon AG
157% Upside
603087
Gan & Lee Pharmaceuticals
24% Upside
LVTX
LAVA Therapeutics NV
42% Upside
NGNE
Neurogene Inc
159% Upside
6855
Ascentage Pharma Group International
12% Upside

Revenue
Forecast

Revenue Estimate
Ascendis Pharma A/S

For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 73%. The projected CAGR for the next 3 years is 69%.

73%
Past Growth
69%
Estimated Growth
Estimates Accuracy
5%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
226.12 USD

According to Wall Street analysts, the average 1-year price target for ASND is 226.12 USD with a low forecast of 195.94 USD and a high forecast of 303.45 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
69%

For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 73%. The projected CAGR for the next 3 years is 69%.

Back to Top